Close X
Attorney Spotlight

What emerging trend in shareholder litigation does Britt Latham find most interesting in his practice today?    Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Gina R. Shockley

Counsel

(901) 543-5916 TEL
(888) 862-9455 FAX

Gina R. Shockley

Counsel

(901) 543-5916 TEL
(888) 862-9455 FAX
(901) 543-5916 TEL
(888) 862-9455 FAX

Gina Shockley counsels biotechnology and pharmaceutical manufacturers, pharmacy and pharmaceutical distribution companies, managed care organizations, pharmacy benefit managers (PBMs), group purchasing organizations, clinical trial and research organizations, and health information technology businesses on all aspects of contracting, regulatory and operational matters. 

Drawing on her years of experience within the pharmacy benefit manager (PBM) and pharmaceutical industry, Gina is able to combine legal guidance with practical business counsel to help companies achieve their business objectives. Gina's practice includes:

  • Pharmaceutical Supply Chain – Advising companies of all sizes on complex strategic projects; negotiating large transactions to ensure compliance with healthcare related laws, including the Anti-Kickback Statute, the False Claims Act (FCA), and the Civil Monetary Penalty Act.
  • Drug Distribution – Providing strategic and contracting support to supply chain participants including pharmacies, manufacturers and PBMs.
  • Regulatory Guidance – Counseling on issues relating to managed care, product liability implications, HIPAA, OIG guidance, fraud and abuse, Foreign Corrupt Practices Act (FCPA), FCA, PhRMA Code, federal and state reporting obligations, and Lanham Act/unfair competition. 

Prior to joining Bass, Berry & Sims, Gina served as Vice President & Associate General Counsel, Supply Chain at Express Scripts, Inc. where she managed the legal support of the supply chain operations for the company across the United States, Canada and the European Union. Before her role at Express Scripts, Gina was an attorney at Eli Lilly and Company, Inc. responsible for legal matters impacting the U.S. and global promotion of certain products.

Memberships

American Health Lawyers Association (AHLA)

News

View More

Accolades

Indiana International & Comparative Law Review – Articles Editor (Fall 2014)

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.